RxDoctor Payments Data

Samantha Kuebler

Physician Assistant · Augusta, GANPI 1538867510

Payments from drug & device makers

$1,469in general payments, 2019–2025

Across 54 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$402
  • Merck$187
  • Sumitomo Pharma America, Inc.$119
  • AbbVie$108
  • Boston Scientific$98
  • Coloplast$87
  • plus $469 from 19 others

What the payments were for

  • Travel & lodging$19914%
  • Food & beverage$1,23484%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,469 in reported general payments places this provider in the 70th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$31,969
Medicare patients
239
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron91$91,699
MyrbetriqMirabegron45$42,681
Tamsulosin Hcl460$5,437
Estradiol61$4,752
Methenamine Hippurate28$2,513
Oxybutynin Chloride ErOxybutynin Chloride122$2,477
Bethanechol Chloride47$2,446
Finasteride141$1,847
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst168$1,665
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl11$1,495
Testosterone15$1,337
Fesoterodine Fumarate ErFesoterodine Fumarate12$1,206
Potassium Citrate ErPotassium Citrate11$1,115
Testosterone Cypionate27$789
Ciprofloxacin Hcl104$443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$119$91,69991 claims
Astellas Pharma US IncMyrbetriq$31$42,68145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →